BMO Capital: 'Rocket Pharmaceuticals (RCKT) Poised for an Asymmetric Rebound in 2Q25+'
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $50.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
